Petrovax Pharm Chief Legal Officer Dmitry Shiskin participated in the conference «Manufacture localization issues in the pharmaceutical industry» hosted by The Moscow Times on June 30 in Moscow.
The event that involved experts from the core ministries focused on examples of successful pharmaceutical construction projects as well as pressing issues of import substitution and production localization such as state support of the companies localizing their manufacturing functions in Russia, funding infrastructural projects, and prospects of signing
state contracts as a result of execution of special investment programs.
Petrovax Pharm shared its experience of participation in international projects associated with
Dmitry Shiskin, speaking at the session «Development of local manufacturing capacities. Facilitation of import substituting manufacture development», cited examples of immunobiological production localization, analyzed problems and possible solutions in this area, presented business partnership arrangements, and remarked on advantages and disadvantages of each partnership type.
«Our company has been operating on the pharma market for about 20 years, and has a vast experience of localization of
products of the world R&D leaders.
Petrovax Pharm manufacturing complex is a
project. It was built in Moscow region in 2008 to GMP standards with financial support and under technical supervision of leading world companies, including EBRD and Solvay Pharma (presently an Abbott Laboratories company). After we have won EBRD’s support, it became easier for us developing international projects given our experience of technical cooperation with Solvay. In 2011, we signed a technology transfer agreement with a Big Pharma company concerning a
production of an advanced pneumococcal vaccine. Since the past year, the product localized at our manufacturing facility in a joint venture setting has been procured by the Russian Ministry of Health for vaccinating children within the National Immunization Schedule. In our opinion, the best type of state support in the dynamically developing market environment is creating equal conditions for pharmaceutical operations irrespective of their type of incorporation, and promoting fair competition," emphasized